Abstract
Background: Prostate cancer is the second most frequent cancer and the fifth leading cause of cancer death in men with higher prevalence in the developed countries. The use of biomarkers for prostate cancer can improve the diagnosis of prostate cancer and clinical management of the patients. Prostate-specific antigen (PSA) is widely used to screen for prostate cancer and there is evidence that PSA testing reduces prostate cancer mortality. Objective: In this report we have studied the relationship between the Gleason score, age and PSA levels of prostate adenocarcinoma tissues from Libyan patients to evaluate the levels of PSA in prostate cancer patients. Materials and methods: The data was collected from medical files of 40 patients who underwent curative surgical prostatectomy or prostate true cut biopsy at National Cancer Institute (NCI)-Misurata, Libya during 2016 to 2018. The clinical and histopathological information included age, PSA levels, and Gleason score grade. Results: Our data showed that PSA level was statistically significant correlation with Gleason score grade (p- value = 0.007, <0.05). The increased serum PSA level was associated with the progression of prostate cancer. However, we found no statistically significant correlation between PSA and the age of patients (p- value = 0.435). Conclusion: Our data confirmed the association of high levels of PSA and the progress of prostate cancer.
Highlights
One of the most main health problems in men is prostate cancer
Our data showed that Prostate-specific antigen (PSA) level was statistically significant correlation with Gleason score grade (p- value = 0.007,
The increased serum PSA level was associated with the progression of prostate cancer
Summary
One of the most main health problems in men is prostate cancer. The rate of prostate cancer surges significantly after the age of 40 years, and around two-thirds of all prostate cancers happen in men of 65 years and older [1]. Some patients have inactive form of disease with no significant effect on mortality for 15 years. PSA is a biomarker that is used for diagnosis and prognosis of prostate cancer. It is the most greatly noninvasive screening tool which causes enhanced detection at earlier stage and decreasing in the number of metastatic patients [4]. PSA is a kallekrein-like serine protease secreted by the epithelial cells of prostate It functions to liquefy serum, promote sperm motility and dissolve cervical mucus [5]. It is present in normal prostatic secretions and is often raised in prostate cancer [6]. Prostate-specific antigen (PSA) is widely used to screen for prostate cancer and there is evidence that PSA testing reduces prostate cancer mortality
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
